Frontier Wealth Management’s Teva Pharmaceuticals TEVA Stock Holding History

Frontier Wealth Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-18,160	Closed	-$836K	–	414
2016 Q3	$836K	Hold	18,160	–	–	0.13%	159
2016 Q2	$912K	Buy	18,160 +5,000	+38%	+$266K	0.15%	144
2016 Q1	$704K	Buy	13,160 +10,000	+316%	+$587K	0.06%	170
2015 Q4	$207K	Sell	3,160 -550	-15%	-$34K	0.03%	314
2015 Q3	$209K	Buy	+3,710	New	+$241K	0.03%	300

Other funds holding TEVA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

HCM

Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Nordea Investment Management Stockholm, Sweden $107B AUM 24.58% 1-Year Est. Return

Frontier Wealth Management's TEVA Position: Q4 2016 in Review

Frontier Wealth Management sold out of Teva Pharmaceuticals (TEVA) in Q4 2016, closing a stake of 18,160 shares — an estimated $836K sold.

Frontier Wealth Management first reported a position in TEVA in Q3 2015 and held it in 5 quarters. The position peaked at $912K in Q2 2016. 737 funds tracked by Wall St. Rank hold TEVA as of Q4 2016.

Frontier Wealth Management reported no remaining Teva Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
Frontier Wealth Management sold 18,160 Teva Pharmaceuticals shares in Q4 2016, an estimated $836K.
Frontier Wealth Management first reported a position in Teva Pharmaceuticals in Q3 2015 and held it in 5 quarters.
Frontier Wealth Management's Teva Pharmaceuticals position peaked at $912K in Q2 2016.
737 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2016.

Based on Frontier Wealth Management's 13F filing for Q4 2016, filed 10 Feb 2017.